Table 2.

Mammographic appearance in relation to oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2) status.

Mammographic appearance	ER−	ER+	OR (95% CI)	p-value	ORadj* (95% CI)	p-value
	n (%)
				< 0.001		< 0.001
Distinct mass	42 (18.4)	186 (81.6)	1.0		1.0
Ill-defined mass	25 (13.9)	155 (86.1)	1.4 (0.8–2.4)	0.221	2.0 (1.1–3.6)	0.022
Spiculated	16 (4.1)	372 (95.9)	5.2 (2.9–9.6)	< 0.001	6.0 (3.2–11.2)	< 0.001
Calcifications	17 (25.8)	49 (74.2)	0.7 (0.3–1.2)	0.192	0.6 (0.3–1.3)	0.191
Tissue abnormality	2 (6.3)	30 (93.8)	3.4 (0.8–14.7)	0.104	4.4 (1.0–19.6)	0.054
Observations			894		867

Mammographic appearance	PR−	PR+	OR (95% CI)	p-value	ORadj* (95% CI)	p-value
	n (%)
				< 0.001		0.007
Distinct mass	96 (43.1)	127 (56.9)	1.0		1.0
Ill-defined mass	77 (44.5)	96 (55.5)	0.9 (0.6–1.4)	0.772	1.1 (0.7–1.7)	0.648
Spiculated	115 (30.9)	257 (69.1)	1.7 (1.2–2.4)	0.003	1.7 (1.2–2.5)	0.003
Calcifications	33 (51.6)	31 (48.4)	0.7 (0.4–1.2)	0.229	0.8 (0.5–1.5)	0.543
Tissue abnormality	17 (54.8)	14 (45.2)	0.6 (0.3–1.3)	0.219	0.9 (0.4–2.1)	0.826
Observations			863		839

Mammographic appearance	HER2−	HER2+	OR (95% CI)	p-value	ORadj* (95% CI)	p-value
	n (%)
				0.005		0.021
Distinct mass	199 (90.5)	21 (9.5)	1.0		1.0
Ill-defined mass	140 (84.8)	25 (15.2)	1.7 (0.9–3.1)	0.096	1.5 (0.8 – 3.0)	0.208
Spiculated	342 (94.5)	20 (5.5)	0.6 (0.3–1.0)	0.069	0.6 (0.3–1.1)	0.107
Calcifications	49 (84.5)	9 (15.5)	1.7 (0.8–4.0)	0.197	2.0 (0.8–5.0)	0.134
Tissue abnormality	29 (93.5)	2 (6.5)	0.7 (0.1–2.9)	0.597	0.7 (0.1–3.1)	0.621
Observations			836		814

*Adjusted for age (categorical), tumour size, mode of detection and breast density.